

Biological Age Estimation Using Circulating Blood Biomarkers

Jordan Bortz (JB)^{1,2,*}; Andrea Guariglia (AG)^{1,2}; Lucija Klaric (LK)¹; David Tang (DT)²; Peter Ward (PW)¹; Michael Geer (MG)¹; Marc Chadeau-Hyam (MC-H)^{2,3,4}; Dragana Vuckovic (DV)^{2,4,*,#}; Peter K Joshi (PKJ)^{1,5,*,#}

(1) Humanity Inc, Humanity, 177 Huntington Ave, Ste 1700, Humanity Inc - 91556, Boston, Massachusetts 02115, United States

(2) Department of Epidemiology and Biostatistics, School of Public Health, Faculty of Medicine, Imperial College London, London, UK

(3) MRC Centre for Environment and Health, School of Public Health, Imperial College London, London, UK

(4) NIHR-HPRU, Health Protection Research Unit in Chemical and Radiation Threats and Hazards, Public Health England and Imperial College London, UK

(5) Centre for Global Health Research, Usher Institute, University of Edinburgh, Edinburgh, UK

*Corresponding authors:

Correspondence to Peter K Joshi (peter.joshi@humanity.email), Dragana Vuckovic (d.vuckovic@imperial.ac.uk) and Jordan Bortz (jordan.bortz@humanity.email).

#Authors jointly supervised this work

ABSTRACT

Biological Age (BA) captures physiological deterioration better than chronological age and is amenable to interventions. Blood-based biomarkers have been identified as suitable candidates for BA estimation. This study aims to improve BA estimation using machine learning models and a feature-set of 60 circulating biomarkers available from the UK Biobank (UKBB) (n = 307,000). We implement an Elastic-Net derived Cox model with 25 selected biomarkers to predict mortality risk, which outperforms the well-known blood-biomarker based PhenoAge model, providing a 9.2% relative increase in predictive value. Importantly, we then show that using common clinical assay panels, with few biomarkers, alongside imputation and the model derived on the full set of biomarkers, does not substantially degrade predictive accuracy from the theoretical maximum achievable for the available biomarkers. BA is estimated as the equivalent age within the same-sex population which corresponds to an individual's mortality risk. Values ranged between 20-years younger and 20-years older than individuals' chronological age, exposing the magnitude of ageing signals contained in blood markers. Thus, we demonstrate a practical and cost-efficient method of estimating an improved measure of BA, available to the general population.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

41 MAIN

42

43 In the past few decades, BA has been estimated using a variety of biomarkers – telomere length, DNA-
44 methylation, proteomics, metabolomics, glycomics, wearable sensor data and blood-based, clinical
45 biomarkers (2, 3, 4, 5, 6, 7). Composite blood-based biomarkers have demonstrated an ability to detect
46 differences in BA even in cohorts of young and healthy individuals, prior to the development of disease
47 or phenotypic manifestations of accelerated ageing (8). When contrasted against some of the omics-
48 based BA estimates, such as epigenetic clocks, blood biomarkers have considerable cost and scalability
49 advantages (9, 10). However, the number of studies on blood biomarker-based BA estimation remains
50 low and further validation is required (2, 11). By making use of a dataset of unprecedented size, this
51 study aims to improve on BA estimation using machine learning methods and address real-world
52 drawbacks, such as sparse data and cost.

53

54 Machine learning techniques have proved to be popular choices in the construction of BA
55 estimates (2, 11, 12, 13). One of the most relevant studies in this domain is Levine *et al.*'s (1) 2018
56 paper, wherein the authors developed a BA measure called PhenoAge, using a Cox proportional-hazards
57 model with an Elastic-Net penalty on data consisting of forty-two blood-based biomarkers and all-cause
58 mortality collected within the NHANES programme. Liu *et al.* (14) subsequently demonstrated that
59 PhenoAge was significantly associated with all-cause and cause-specific mortality, even after adjusting
60 for chronological age (CA) and sex.

61

62 In this study, we used a dataset of 57 blood-biomarkers (Supplementary Table 1) and all-cause
63 mortality from 306,756 participants from the UK Biobank (UKBB) dataset
64 (<https://www.ukbiobank.ac.uk/>). Participants' ages ranged from 37 to 73 years, with a mean of 56.3
65 years. The overall mortality rate of the population was 4.3% for females (6,515) and 7.8% for males
66 (12,215), with a total of 18,730 recorded deaths. Follow-up duration ranged from 0.01 years to 14 years
67 (average of 11.6 years) (Supplementary Table 2).

68

69 We built an Elastic-Net penalised Cox proportional-hazards model, as the foundation of our
70 BA prediction, using survival time as outcome and blood biomarkers as predictors, while adjusting for
71 sex and age, which were not penalised. As a non-linear alternative accounting for possible interactions
72 we also constructed a Random Survival Forest (RSF) (15). Predictive performance of all models was
73 evaluated using Harrell's Concordance Index ("C-index" or "concordance statistic"), which is the most
74 used measure of predictive discrimination in the context of survival models (16, 17).


75

76 We trained 100 Cox proportional-hazards models with Elastic-Net penalty, each on a 50%
 77 subsample of the training data (80-20 train-test split). Using a stability selection approach, we calculated
 78 the per-variable selection proportions across each of the 100 calibrated models as a proxy for their
 79 importance. We considered variables with selection proportion >80% to be stably selected (Fig 1a). A
 80 total of 25 (of the 57) biomarkers were stably selected, of which 22 had a selection proportion >95%.
 81 Reducing the selection proportion threshold to 50% would only have resulted in the inclusion of 4
 82 additional variables. The ensemble of 25 stably selected features along with age and sex were included
 83 in a final unpenalized Cox model which we label the “Full Elastic-Net Cox (ENC)” model. The Full
 84 ENC model resulted in a C-Index of 0.762 with 95% confidence interval of [0.754 – 0.770] on the test
 85 set, showing improvement over (i) the model including sex and age only (null model) with a C-Index
 86 of 0.715 [0.707 – 0.723] and the PhenoAge model with C-Index of 0.739 [0.731 – 0.747] (Fig 1b).

87

88 **Fig 1: The Full Elastic-Net Cox model performs similarly to the Random Survival Forest and**
 89 **produces robust mortality risk predictions across both healthy and sick groups.**

90



91 **(a)** Selection proportions of each feature as a percentage of the 100 Elastic-Net iterations performed, ranked from
 92 highest to lowest. The adopted selection threshold of 80% is indicated in red. **(b)** Bar plot comparing the C-Index
 93 values (and 95% CI) of (1) a Cox model using sex and age only (null model), (2) the PhenoAge model applied on
 94 the UKBB data, (3) our RSF and (4) our Elastic-Net derived Cox-model (Full ENC). **(c)** Comparison of C-Index
 95 values of the Full ENC and sex-and-age-only null models for Healthy and Sick groups. For both groups, C-Index
 96 values of the Full ENC were significantly higher than those produced by the null model, with non-overlapping
 97 confidence intervals, indicating that the Full ENC model provides a statistically significant uplift in predictive
 98 ability. The dashed horizontal lines represent the C-index values of the Full ENC and the null model on the
 99 combined test set (Healthy + Sick).

100

101
 102 The tuned RSF yielded a very similar result to the Full ENC model with a C-Index estimate of
 103 0.761 [0.751 – 0.772] on the test set (Fig 1b), hence not supporting non-linear effects nor the existence
 104 of complex interactions across biomarkers. With a value of 0.5 corresponding to random prediction, we
 105 consider the predictive uplifts of models to be the additive increase above 0.5. The additive increases

106 of 0.262 and 0.261 for the Full ENC and RSF models, compared to 0.215 for the null model, indicate a
107 22% and 21% increase in predictive value, respectively. Similarly, both models outperformed the
108 PhenoAge model applied on the UKBB data, with a 0.023 increase in C-index (9.2% increase in
109 predictive value).

110

111 As a sensitivity analysis to assess predictive ability and generalisability of the ENC model we
112 stratified the test set by a self-reported, binary indicator of “long-standing illness, disability, or
113 infirmity” (18, 19) and reported the corresponding C-Indices yielded by the null and ENC models
114 trained on the full training dataset. The C-Index for those not reporting a prevalent condition at baseline
115 (“Healthy”) was 0.740 [0.729 – 0.752] for the ENC model, which is higher than that from the null model
116 at 0.717 [0.705 – 0.728]. In the group of participants reporting a prevalent condition (“Sick”) the
117 estimated C-Index was comparable at 0.750 [0.739 – 0.761] for the ENC model and 0.685 [0.673 –
118 0.696] for the null model. In both groups of participants, the ENC model yielded an increase in the C-
119 index compared to that of the null model, corresponding to 11% and 30% increases in predictive value,
120 for the Healthy and Sick groups respectively. This stratified analysis suggests that the blood biomarkers
121 detected by the ENC model are jointly predictive of mortality risk irrespective of prevalent morbidity.

122

123 Practical application of blood-based BA estimation will be facilitated by the use of existing
124 results from assays which individuals have obtained for various clinical reasons. In principle, any
125 subset of the 25 biomarkers might be available (i.e. >33 million combinations), although, in reality,
126 clinical practice will tend to result in some subsets being more common than others. We researched
127 which panels corresponded to the most performed blood tests in the UK as part of regular medical
128 check-ups, employer-based testing, or diagnostic testing, within the NHS or by private providers (20,
129 21, 22) and identified the 10 most commonly available panels of markers (Supplementary Table 3).
130 Similar, bespoke Elastic-Net Cox models were developed on the training set for each of these 10
131 representative panels of markers separately and we report the corresponding C-Indices in the test set
132 (Fig 2, maroon bars). These C-Indices estimate the theoretical maximum of predictive accuracy for
133 individuals who have had only these assays measured.

134

135 The performance of each of these per-panel models was compared to the performance of the
136 Full ENC model, where we considered biomarkers not included in the panel to be unavailable, and were
137 thus imputed using the k-Nearest Neighbour (kNN) method (23).


138

139

140

141

142 **Fig 2: Imputing out-of-panel biomarkers and using the Full ENC model did not substantially**
 143 **reduce predictive accuracy compared to bespoke models for each representative panel**
 144
 145



146

147 Comparison of concordance values across bespoke models vs imputed ENC models, for each of the 10 real-world
 148 representative blood panels, on the test set. Sex and age were also included as (unpenalised) features in all models.
 149 The number in brackets next to the panel name indicates the panel number as per Supplementary Table 3. The
 150 number in square brackets indicates the count of biomarkers (b=) in the panel. The performance of the impute-
 151 then-Full-ENC method is similar to that of the bespoke models, especially for the more comprehensive panels.
 152 The green dashed horizontal line indicates the 0.715 C-Index of the (sex and CA only) null model, whilst the blue
 153 line indicates the 0.762 C-Index of the Full ENC model with all 25 selected biomarkers measured. “+CC” indicates
 154 the addition of cystatin C to the panel (panels 4 and 10).

155

156 For all panels, except panel 3, there were no significant differences in C-Index values across
 157 both methods. The average reduction in C-index across all panels was 0.0087, whilst the reduction in
 158 C-index values for the top five performing panels (panels 1,8,7,9 and 10) was only 0.0036. These results
 159 appear to suggest that, for most panels, there is no substantial loss in predictive accuracy when imputing
 160 and using the ENC model compared to bespoke models.

161

162 After imputation, the ENC model for the top five performing panels yielded an average
 163 improvement in C-Index of 0.0273 over the sex-and-age-only null model (Fig 2, green line), and an
 164 average reduction in C-index of 0.0197 against the Full ENC model with all 25 selected biomarkers
 165 available (Fig 2, blue line). For panels 2 and 3, the ENC model yielded a C-index of 0.704 [0.696 –
 166 0.712]and 0.701 [0.692 - 0.708], respectively, which is slightly lower than that of the sex-and-age-only
 167 model at 0.715 [0.707 – 0.723], suggesting that the imputation of missing variables was sufficiently
 168 imprecise to push predictions away from the point of utility.

169 Standardised model coefficients and 95-percent confidence intervals on the log hazard scale for
170 the Full ENC model are displayed in Fig 3a. Increasing age, male sex and increased levels of cystatin
171 C appear to have the strongest effects towards an increasing hazard rate, whilst high levels of creatinine,
172 alanine aminotransferase and vitamin-D are associated with lower hazard rates. For the RSF, variable
173 importance (VIMP) values were also generated. As was seen in the Full ENC model, age is the most
174 important variable, followed by cystatin C, which appears to have a higher importance value than sex
175 in the RSF (Supplementary Figure 2).

176 The Full ENC model coefficients are compared to the coefficients as per Levine *et al.*'s
177 PhenoAge (1) model in Fig 3b. The 10 variables in the PhenoAge model, derived from the NHANES
178 dataset, were also stably selected in our ENC model except overall WBC count, which was substituted
179 in our model by individual WBC components (monocytes, neutrophils, and lymphocytes). Model
180 coefficients appear to be remarkably similar between the PhenoAge model and our ENC model, except
181 creatinine, which had a small, negative effect size in our model, in contrast to a small, positive effect in
182 the PhenoAge model. Overall, these consistent results provide validation of the effect that these
183 variables in two large, independent cohorts. Our model additionally included sex and selected 17
184 additional biomarkers, some of which have the largest standardised coefficients and were not considered
185 in the derivation of PhenoAge. The complete set of model coefficients is also shown in Supplementary
186 Table 4 alongside implied hazard ratios.

187 The ENC model suggests that a one standard deviation increase (i) in age (8.1 years) increases
188 mortality hazard by 84% [95% CI: 80% - 88%], (ii) in cystatin C (0.14mg/L) by 31% [29% - 33%],
189 when adjusted for sex and all selected biomarkers (Supplementary Table 4). Our result mirrors the
190 finding of a meta-analysis by Luo *et al.* (24), which identified a 32% [12% - 55%] increase in all-cause
191 mortality hazard with a one standard deviation increase in cystatin C, based on 39,000 participants
192 across nine different studies. The addition of cystatin C to the Comprehensive Metabolic Panel and the
193 Employer/Cardiac Panel confirmed the incremental predictive uplifts in models where this biomarker
194 is present, increasing the C-index by 0.015 and 0.005 for each of the Panels respectively (Fig 2, panels
195 3 vs 4 and 9 vs 10). Red blood cell (erythrocyte) distribution width appears to have the strongest effect
196 size after cystatin C, with a standard deviation increase implying a 17% [15% - 19%] increase in
197 mortality hazard.

198

199


200

201

202

203 **Fig 3: Our results confirm relationships suggested by Levine *et al*'s PhenoAge model, and**
204 **additionally suggest that cystatin C is the biomarker of primary importance in BA estimation.**

205



206

207 **(a)** Bar chart showing standardised Cox model coefficients and 95% confidence intervals (log hazard scale) of the
208 Full ENC model developed using stably selected variables, ranked in descending order. Coefficients are
209 standardised (i.e. rescaled) by multiplying by the standard deviation of the variable concerned. Red indicates that
210 higher levels increase mortality hazard; blue indicates that higher levels reduce mortality hazard. Apart from age
211 and sex, cystatin C appears to have the strongest effect size. **(b)** Comparison of coefficient values between Levine
212 *et. al*'s PhenoAge coefficients (green) and our Elastic-Net derived Cox model (blue). Model coefficients are
213 similar across both models. Our ENC model selected individual WBC components (monocytes, neutrophils and
214 lymphocytes) rather than overall WBC count. Measurement units for biomarkers were the same across both
215 models.

216 Due to the documented positive relationship between serum cystatin C and creatinine (25, 26),
217 as well as the positive correlation ($r = 0.51$) identified in our descriptive analysis (Supplementary Figure
218 1), we investigated how the effect sizes of these two biomarkers were altered with the removal of the
219 other. When creatinine was removed, the standardised effect size for cystatin C was still the largest of
220 all blood biomarkers. The hazard ratio decreased to a 22% [20% – 24%] increase in mortality hazard
221 for one standard deviation increase in cystatin C level. Conversely, when cystatin C was removed, the
222 effect size for creatinine was still negative but was no longer statistically significant, with a one standard
223 deviation increase implying a 1% [-1% to 3%] reduction in mortality hazard.


224 The ENC model was used to estimate Biological Age Acceleration (BAA), representing the
225 additional years of physiological deterioration above that implied by one's CA (i.e., the difference
226 between BA and CA), as explained in Methods. Most BAA values ranged from -20 to 20 years, with
227 an interquartile range of 7 years, centered around a median value of -0.47 with a slight right skew (Fig
228 4a), similar to the results obtained by Liu *et al.* (14). However, the range of age acceleration seen in Liu
229 *et al.* (14), of -3 to 6, is substantially narrower than our BAA range, which could at least partially be
230 attributed to the differences in methodology used to derive BAA. It could also represent the additional

231 sensitivity introduced in our model due to the inclusion of 17 additional circulating biomarkers, as well
232 as the adjustment for sex.

233

234 **Fig 4: Biological Age Acceleration values range between -20 and 20, and reflect mortality risk**
235 **even in same-age groups.**

236



237

238 (a) Distribution of estimated BAA values on the test set. Blue indicates a negative BAA ($BA < CA$), and red
239 indicates a positive BAA ($BA > CA$). The distribution is largely symmetric around 0, with most values ranging
240 between -20 and 20. (b-d) Kaplan-Meier curves comparing survival probabilities for the top and bottom BAA
241 quintiles for each of the three age categories in the test set. Green indicates the bottom quintile (largest negative
242 BAA values) whilst red indicates the top quintile (largest positive BAA values). Notable differences are
243 observed between quintiles, especially at older ages.

244

245 As proposed by Liu *et al.* (14), we considered 3 broad age groups ($[<=50]$, $(50-65]$, $(65+)$),
246 and plotted the Kaplan-Meier curves for the top and bottom quintiles of BAA values within each age
247 group (Fig 4b-4d). The plots demonstrate that BAA provides an indication of BA and mortality risk
248 even at the youngest ages in the dataset (<50 years of age at recruitment). The log-rank test was
249 significant for all age groups ($p < 0.0001$). Notably, the mortality rates for those in the highest BAA

250 quintile in an age group were higher than those in the lowest BAA quintile in the older age group. For
251 example, those in the highest quintile of BAA in the ≤ 50 age group experienced higher mortality rates
252 than those in the lowest quintile of the 50 - 65 age group, over the next 14 years of follow-up.

253

254 As a final sensitivity analysis, we conducted similar analyses in males and females separately
255 (Supplementary Note). The resulting C-index values, effect size estimates, and BAA predictions were
256 similar to those obtained in the full population. Sex-stratified models did not produce more accurate
257 predictions than the Full ENC model, even within same sex groups.

258

259 In this analysis, we demonstrated that circulating biomarkers have the potential to form the
260 foundations of an accurate and low-cost measure of BA, via a simple formula. Our BA estimates ranged
261 between 20-years younger and 20-years older than individuals' chronological age, exposing the extent
262 of ageing signals contained within the selected biomarkers. Our Elastic-Net derived Full ENC model,
263 which selected 25 biomarkers, outperformed the alternative blood-biomarker based PhenoAge model
264 (1), providing a 9.2% relative increase in predictive value. We do, however, acknowledge that our Full
265 ENC model was both trained and evaluated within the UKBB cohort of participants.

266

267 Importantly, the model developed in this study possesses translational value in the real-world
268 setting, where pre-existing measures of blood biochemistry will often be available but will vary greatly
269 across individuals. We established that imputing values for unmeasured blood markers and
270 subsequently using the Full ENC model, did not substantially degrade predictive accuracy away from
271 what would be achieved by developing bespoke, per-panel models. The average reduction in C-Index
272 across all panels, including the poor performing panels, was 0.0087, whilst the reduction for the top
273 five panels was 0.0036. This suggests that the Full ENC model could be used to estimate BA values
274 practically and accurately, in a real-world setting, irrespective of the number of biomarkers available.
275 The ability of our BAA to distinguish between high risk and low risk individuals within same-age and
276 same-health groups in our sample is an indication that BAA can identify physiological deterioration
277 even in younger and healthy populations.

278 Our findings follow the trajectory of the growing literature in the field of BA, where numerous
279 clocks have been developed which are predictive of future morbidity and mortality outcomes (2, 5). In
280 particular, our focus on practicality and translational value was influenced by the blood-based
281 PhenoAge (1) and GrimAge (27) BA estimators, which were shown to correlate with all-cause mortality
282 even in same-age groups. We have demonstrated that such ageing clocks can indeed be employed highly
283 cost effectively, using pre-existing or readily available blood results.

284 Our study benefited from several important strengths including the large sample size and the
285 substantial number of biomarker measurements available, which enabled the development of robust
286 inference, including stratified analyses and the use of interpretable machine learning techniques.
287 However, the use of the UKBB dataset comes with well-documented limitations. The healthy volunteer
288 bias inherent in the selection of participants, as well as the ethnic composition of participants (95%
289 white), have been well documented in the literature (28). The homogeneity of the study population as
290 well as the standardisation of measurement protocols across blood samples within the UKBB may not
291 reflect systematic variation in blood results across different laboratories and populations. We do,
292 however, acknowledge the remarkably similar parameters of Levine *et al's* (1) PhenoAge model, which
293 were based on the North-American, NHANES dataset, providing an independent validation of our
294 findings using an external data source. An additional limitation relates to our imputation approach,
295 which occurred within the single UKBB cohort. This approach may overestimate imputation quality in
296 reality, where relationships between biomarkers in different population groups may differ from those
297 observed in the UKBB.

298

299 Our findings are consequential in an era of rapidly ageing populations. Practical mechanisms
300 for identifying biological ageing and scientifically informed ageing-reversal interventions are essential
301 to maximising population healthspan and reducing pressure on healthcare providers.

302

303

304 **METHODS**

305

306 **Data Source and Data Processing**

307

308 The data used in this study forms part of the UK Biobank (UKBB) dataset. The 502,536 participants in
309 the UKBB, recruited between 2006 and 2010 in England, Scotland, and Wales, were aged between 37
310 and 73 years at recruitment (29). Participants represented a range of socioeconomic, ethnic, and
311 urban/rural population groups (29). Full details of the UKBB study, including details of recruitment and
312 data collection, can be found on the UKBB website (<https://www.ukbiobank.ac.uk/>), and supplementary
313 information can be obtained in Sudlow *et al.* (29). The specific data fields used in this analysis were
314 date of recruitment, age at recruitment, sex, date of death (if applicable), presence of illness or disease
315 at recruitment (self-reported), and a range of 60 blood biochemistry and haematology markers, samples
316 of which were obtained from participants at recruitment. The full list of the blood biomarkers available
317 in the UKBB, prior to the data cleaning and further sub-selection detailed below, can be found in
318 Supplementary Table 1, alongside their measurement units. Additional details on these markers can be
319 found in the UK Biobank Companion Documents (30, 31, 32).

320

321 Data fields were examined for missing values and any fields where more than 20% of
322 observations contained missing values were removed (lipoprotein-A, oestradiol and rheumatoid factor).
323 For the remaining fields, the underlying reasons for missingness were investigated, per biomarker, using
324 the UKBB data showcase resources
325 (<https://biobank.ndph.ox.ac.uk/showcase/label.cgi?id=100080>). Blood assay data in UKBB may
326 be missing for a variety of reasons, such as aliquot or aliquot dilution problems, values being below the
327 reportable limit, and no data being obtained from a sample. An examination of the underlying causes
328 informed subsequent handling of data, and the appropriateness of proceeding under a complete case
329 analysis. For example, if missing values were largely driven by measured levels being below the
330 minimum limit of detection, omitting such individuals would exclude individuals with low levels of a
331 biomarker from this study, biasing results. For all biomarkers, apart from testosterone, the reasons for
332 missing values appeared to be independent of both the biomarker and the participant and were primarily
333 caused by aliquot errors or aliquot dilution problems. We therefore proceeded under a complete case
334 analysis, assuming that data was largely missing completely at random. The final dataset consisted of
335 306,756 observations, each having 57 blood biomarkers, alongside sex and age. Data was examined for
336 outliers, and a log-transformation was applied to variables with strong positive skew (alanine
337 aminotransferase, aspartate aminotransferase, gamma glutamyltransferase, C-reactive protein, sex
338 hormone binding globulin (SHBG), testosterone, total bilirubin, triglyceride and vitamin-D). The final
339 dataset was then randomly split into a training and test set in the ratio 80:20, and these were used in the
340 remainder of the study.

341

342 **Model Performance**

343

344 Predictive performance of all models was evaluated using Harrell's Concordance Index ("C-index" or
345 "concordance statistic"), which is the most commonly used measure of predictive discrimination in the
346 context of survival models (16, 17). Concordance is defined as the probability that the magnitude of the
347 predicted values for observations i and j (p_i and p_j), rank in the same order as the actual values for these
348 observations, a_i and a_j :

349

$$350 P(p_i > p_j | a_i > a_j).$$

351

352 In other words, the probability that, for a pair of observations, the observation that experiences
353 an event first, had a worse predicted outcome. The pair of observations is considered concordant if the
354 rankings of the predicted and actual values are the same and are discordant otherwise. Ignoring ties, the
355 Concordance Index is then defined as:

356

357 $ConcordantPairs/(ConcordantPairs + DiscordantPairs)$

358

359 A concordance value of 0.5 corresponds to a model that is no better than a random guess, and
360 a value of 1 would imply a perfect model. In the presence of censoring, some pairs cannot be compared
361 or classified as concordant nor discordant. For example, pairing an individual who is censored at year
362 5 against an individual who experiences a mortality event at year 10 (17).

363

364

365 **Cox Proportional-Hazards Model with Elastic-Net Penalty and Stability Analysis**

366

367 Using the training dataset, we developed 100 Elastic-Net Cox proportional-hazards models, using
368 survival time and mortality indicator as outcome, each using a subsample of 50% of the dataset, as
369 suggested by Bodinier *et al.* (33). For each iteration, 10-fold cross validation was used to select the
370 optimal parameters, lambda and alpha, that minimised the partial likelihood deviance statistic, across a
371 grid of 80 lambda values and alpha values between 0 and 1. As is commonly done in penalised
372 regression models, we selected the (larger) lambda value that corresponded to a deviance statistic of
373 one standard error above the minimum during cross-validation (lambda 1-s.e.) (34). The penalisation
374 was only applied to the biomarker variables and neither sex nor age were penalised in any of the Elastic-
375 Net models. All variables were standardised for the Elastic-Net optimisation process.

376

377 Stability analysis was performed to improve the predictive accuracy and the reliability of the
378 model, ensuring that variable selection was not driven by outliers or a particular subset of observations
379 (33). For each variable, we calculated the proportion of the 100 iterations in which the variable was
380 selected, and its standardised coefficient value, as indicators of its relative importance. A selection
381 proportion of 80% was used to determine if a variable was selected stably (35). These stably selected
382 variables were then included in a non-penalised Cox model, to produce the final regression equation,
383 which was used to generate predictions. This model is labelled the Full Elastic-Net Cox (ENC) model,
384 where “full” indicates the use of all available biomarkers in model training along with age and sex.

385

386 This approach was used both for the model developed on the full set of biomarkers as well as
387 for the 10 bespoke models developed for each of the 10 representative real-world blood panels. The
388 Elastic-Net models were developed using the *survival* (36) and *glmnet* (37) packages in R version 4.1.3
389 (38).

390

391

392

393 **Biological Age Acceleration**

394

395 We required an interpretable format of presenting an individual's relative increase or decrease in
396 mortality risk in relation to one's CA, based on blood biochemistry. Biological Age Acceleration (BAA)
397 is defined as the additive difference between one's model-implied BA and one's CA, adjusted for sex.
398 To quantify this age acceleration, we decomposed the Cox model equation on the log scale as follows:

399

$$400 \quad \log(\text{HazardRate}) = \log(\text{BaselineRate}) + X_{AS}\beta_{AS} + X_B\beta_B$$

401

402 where X_{AS} represents the $[n \times 2]$ matrix of age and sex covariate values, β_{AS} represents the $[2 \times 1]$ vector
403 of corresponding age and sex effect sizes (beta coefficients), X_B represents the $[n \times 57]$ matrix of
404 biomarker values, β_B represents the $[57 \times 1]$ vector of corresponding biomarker effect sizes. Setting the
405 first 2 terms on the righthand side of the equation as constant K , for an individual of a given age and
406 sex:

407

$$408 \quad \log(\text{HazardRate}) = K + \log(\text{HazardRatioBloodBiomarkers})$$

409

410 where $\log(\text{HazardRatioBloodBiomarkers})$ is equivalent to the product $X_B\beta_B$. Using the relationship
411 between log hazard ratio and age as suggested by Joshi *et al.* (39), where a log hazard ratio of Y indicates
412 an additive change in age of approximately $10Y$, we multiplied the product $X_B\beta_B$ by 10, to quantify the
413 vector of BAA values. That is:

414

$$415 \quad BAA = 10 \times X_B\beta_B$$

416

417 We independently checked this log-hazard-ratio:years-of-age relationship, by producing a
418 Kaplan-Meier curve over age using the full UKBB dataset of 500,000 participants, and separately using
419 data from the English Life Table No.17 (ELT-17) (40). Based on the results, we were satisfied that the
420 relationship was sufficiently accurate to form the foundations of our BAA estimate. The results from
421 this investigation can be seen in Supplementary Tables 5 – 7. Note that for the purposes of the BAA
422 calculation, all blood biomarker variables in X_B were centred, by subtracting the (test set) mean value
423 for each biomarker in the test set. This implies that BAA would equal to zero for a theoretical individual,
424 of any age or sex, who holds the average value for each of the selected biomarkers.

425

426 Once BAA estimates had been derived as per the above method for the test set, we examined
427 the range and distribution of BAA across observations. We also examined the association between BAA

428 and mortality, by producing Kaplan-Meier curves for the lowest quintile and the highest quintile of
429 BAA respectively. We did this across three age groups separately: 50 and younger, 50–65, and 65 years
430 and older, which allowed for a comparison of mortality between BAA quintiles across different age
431 groups. Kaplan-Meier curves were constructed using the *survival* (36) and *survminer* (41) packages in
432 R.

433

434 **Random Survival Forest**

435

436 A Random Survival Forest (RSF) was trained and the resulting C-Index value on the test set was
437 compared to that achieved by the Full ENC model. A RSF is an extension of Breiman’s Random Forest
438 method (42), applied to right-censored survival data (15). In the survival model setting, nodes are split
439 according to the maximisation of the log-rank test statistic (15). The RSF has the potential to outperform
440 the Cox model, as it can inherently handle nonlinear and interaction effects (15). We used the
441 *randomForestSRC* (43) package in R to develop our RSF models.

442

443 Tuning was iteratively performed, maximising out-of-bag Concordance Index, for three hyper-
444 parameters in particular: number of variables considered at each split, minimum node size and number
445 of trees. The initial tuning was performed on a wide grid of these three hyper-parameter values, with
446 each of the two successive rounds of tuning taking place over a smaller range of values, around the
447 current optimal point. Three possible split points were considered for each continuous variable, at each
448 split. The final optimal values for the number of variables considered at each split, and the minimum
449 node size were 21 and 130 respectively, for an ensemble of 150 trees. The tuned model was then applied
450 on the test set. The predicted outcome, per terminal node, is the Nelson-Aalen estimator for the
451 cumulative hazard function, calculated on all the training observations in that terminal node. The
452 average predicted cumulative hazard function value across all trees is then compared to the actual
453 survival outcome, per pair of observations in the test set, to compute the C-Index.

454

455 We also produced Variable Importance (VIMP) scores, which provide an indication of which
456 variables in the dataset hold the highest predictive ability (15). The VIMP ordering from the RSF was
457 compared against the selection proportions and standardised coefficients from the Cox Elastic-Net
458 stability analysis.

459

460 **Representative, Real World Blood Panels**

461

462 We researched which panels corresponded to the most commonly performed blood tests in the UK as
463 part of regular medical check-ups, employer-based testing, or diagnostic testing, within the NHS or by

464 private providers (20, 21, 22). These panels are summarised in Supplementary Table 3. We decided to
465 explore certain panels with and without the inclusion of cystatin C. This was done for two reasons.
466 Firstly, cystatin C does not consistently form part of these blood panels; certain sources included it,
467 whilst others did not. Secondly, during the course of our investigation, we observed the strong predictive
468 ability of cystatin C in our own preliminary results. In light of these two reasons, we decided to test the
469 sensitivity of performance between panels that did and did not include cystatin C.

470

471 We investigated the performance of the Full ENC model, applied on each of these
472 representative panels. To do so, for each of the ten panels, we imputed the notionally unmeasured values
473 of the biomarkers in the test set which were required by the Full ENC model, but were not present in
474 the notional panel set, using k-Nearest Neighbours (kNN) imputation ($k = 5$) based on a random sample
475 of 10,000 individuals from the training set. Variables were standardised for the KNN imputation, which
476 was performed in R using the *VIM* package (23). For ease of reference, we label this approach the
477 “impute-then-Full-ENC” method. In each of these 10 cases, the performance of the impute-then-Full-
478 ENC prediction was compared against performance of each of 10 bespoke ENC models developed
479 specifically on the biomarkers present in each of the ten representative panels, alongside sex and age.
480 The bespoke models represent an estimate of the theoretical maximum of predictive accuracy for
481 individuals who have had only these assays measured.

482

483 Note that a single, consistent test set was used to evaluate the performance of each and every
484 one of the models in this study, removing any variability that would be introduced by altering the
485 composition of the observations in the test set.

486 **DATA AVAILABILITY**

487

488 The data used for this study is available to all qualified researchers via the UK Biobank data access
489 process.

490

491 **CODE AVAILABILITY**

492

493 The code used and resultant models for this project are the intellectual property of Humanity Inc.

494

495 **AUTHOR CONTRIBUTIONS**

496

497 JB, PKJ, DV, DT, AG, PW, and MG participated in conceiving the study objectives and design. JB,
498 PKJ and AG carried out initial data preparation. JB performed the data analysis and model
499 development with support from PKJ, DV, LK, and DT. JB wrote the first draft of the manuscript. All
500 authors revised and provided critical commentary on the manuscript. PKJ and DV jointly supervised
501 this work.

502 **ACKNOWLEDGEMENTS**

503

504 We thank the UK Biobank Resource, approved under application 69634. We acknowledge funding
505 from Humanity Inc, a company dedicated to measuring and improving biological age. JB was
506 supported by a Commonwealth Scholarship at Imperial College London, funded by the UK Foreign,
507 Commonwealth & Development Office (FCDO). DV and MC-H are members of the Health
508 Protection Research Unit in Chemical and Radiation Threats and Hazards, a partnership between
509 Public Health England and Imperial College London which is funded by the National Institute for
510 Health Research (NIHR). Neither the FCDO nor the NIHR had a role in the study design, data
511 analysis, preparation of manuscript or decision to publish.

512

513 **ETHICS DECLARATIONS**

514

515 PKJ and JB are paid consultants to Humanity Inc, a company focussed on measuring and developing
516 interventions for Biological Age. LK is an employee of Humanity Inc. AG was formerly a paid
517 consultant of Humanity Inc. MG and PW are founders of Humanity Inc and are employees and hold
518 ordinary shares. PKJ, LK, MG and PW are partly remunerated under a Humanity Inc share option
519 scheme. PKJ is founder of Geromica, a consultancy providing advice on measurement of health and
520 aging. MC-H holds shares in the O-SMOSE company and has no conflict of interest to disclose.
521 Consulting activities conducted by the company are independent of the present work.

522

523 Human subjects: This work used existing datasets, for which ethical approval had been gathered for
524 health investigation at the time of collection.

525 REFERENCES

526

- 527 1. Levine ME, Lu AT, Quach A, Chen BH, Assimes TL, Bandinelli S, et al. An epigenetic biomarker
528 of aging for lifespan and healthspan. *Aging (Albany NY)*. 2018;10(4):573.
- 529 2. Jylhävä J, Pedersen NL, Hägg S. Biological age predictors. *EBioMedicine*. 2017;21:29-36.
- 530 3. Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of
531 ageing. *Nature Reviews Genetics*. 2018;19(6):371-84.
- 532 4. Frenck Jr RW, Blackburn EH, Shannon KM. The rate of telomere sequence loss in human
533 leukocytes varies with age. *Proceedings of the National Academy of Sciences*. 1998;95(10):5607-10.
- 534 5. Macdonald-Dunlop E, Taba N, Klarić L, Frkatović A, Walker R, Hayward C, et al. A catalogue of
535 omics biological ageing clocks reveals substantial commonality and associations with disease risk.
536 *Aging (Albany NY)*. 2022;14(2):623.
- 537 6. Krištić J, Vučković F, Menni C, Klarić L, Keser T, Beceheli I, et al. Glycans are a novel biomarker
538 of chronological and biological ages. *Journals of Gerontology Series A: Biomedical Sciences and
539 Medical Sciences*. 2014;69(7):779-89.
- 540 7. Pyrkov TV, Sokolov IS, Fedichev PO. Deep longitudinal phenotyping of wearable sensor data
541 reveals independent markers of longevity, stress, and resilience. *Aging (Albany NY)*. 2021;13(6):7900.
- 542 8. Belsky DW, Caspi A, Houts R, Cohen HJ, Corcoran DL, Danese A, et al. Quantification of
543 biological aging in young adults. *Proceedings of the National Academy of Sciences*.
544 2015;112(30):E4104-E10.
- 545 9. Vidal-Bralo L, Lopez-Golan Y, Gonzalez A. Simplified assay for epigenetic age estimation in
546 whole blood of adults. *Frontiers in genetics*. 2016;7:126.
- 547 10. Wolinsky H. Testing time for telomeres: telomere length can tell us something about disease
548 susceptibility and ageing, but are commercial tests ready for prime time? *EMBO reports*.
549 2011;12(9):897-900.
- 550 11. Sebastiani P, Thyagarajan B, Sun F, Schupf N, Newman AB, Montano M, et al. Biomarker
551 signatures of aging. *Aging cell*. 2017;16(2):329-38.
- 552 12. Gruenewald TL, Seeman TE, Ryff CD, Karlamangla AS, Singer BH. Combinations of biomarkers
553 predictive of later life mortality. *Proceedings of the National Academy of Sciences*.
554 2006;103(38):14158-63.
- 555 13. Belsky DW, Caspi A, Arseneault L, Baccarelli A, Corcoran DL, Gao X, et al. Quantification of the
556 pace of biological aging in humans through a blood test, the DunedinPoAm DNA methylation
557 algorithm. *Elife*. 2020;9:e54870.
- 558 14. Liu Z, Kuo P-L, Horvath S, Crimmins E, Ferrucci L, Levine M. A new aging measure captures
559 morbidity and mortality risk across diverse subpopulations from NHANES IV: a cohort study. *PLoS
560 medicine*. 2018;15(12):e1002718.
- 561 15. Ishwaran H, Kogalur UB, Blackstone EH, Lauer MS. Random survival forests. *The annals of
562 applied statistics*. 2008;2(3):841-60.
- 563 16. Harrell Jr FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models,
564 evaluating assumptions and adequacy, and measuring and reducing errors. *Statistics in medicine*.
565 1996;15(4):361-87.
- 566 17. Therneau T, Atkinson E. 1 The concordance statistic [Internet]. 2020. Cited 29 June 2022.
567 Available at: <https://cran.r-project.org/web/packages/survival/vignettes/concordance.pdf>.
- 568 18. UK Biobank. Data-Field 2188; *Long-standing illness, disability or infirmity* [Internet]. Updated
569 2012. Cited 17 August 2022. Available at: <https://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=2188>.
- 570 19. Mutz J, Roscoe CJ, Lewis CM. Exploring health in the UK Biobank: associations with
571 sociodemographic characteristics, psychosocial factors, lifestyle and environmental exposures. *BMC
572 medicine*. 2021;19(1):1-18.
- 573 20. NHS UK. *Blood Tests - Examples* [Internet]. Updated 2018. Cited 14 June 2022. Available at:
574 <https://www.nhs.uk/conditions/blood-tests/types/>.

- 575 21. Bupa. 2022. *Diagnostics, Tests and Scans* [Internet]. Updated 2022. Cited 14 June 2022.
576 Available at: <https://www.bupa.co.uk/health/payg/gp-services/diagnostics-tests-and-scans>.
- 577 22. Ramsay Health Care. *Cardiac Blood Tests* [Internet]. Updated 2022. Available at:
578 <https://www.ramsayhealth.co.uk/treatments/cardiology/cardiac-blood-tests>.
- 579 23. Kowarik A, Templ M. Imputation with the R Package VIM. *Journal of Statistical Software*.
580 2016;74:1-16.
- 581 24. Luo J, Wang L-P, Hu H-F, Zhang L, Li Y-L, Ai L-M, et al. Cystatin C and cardiovascular or all-cause
582 mortality risk in the general population: a meta-analysis. *Clinica chimica acta*. 2015;450:39-45.
- 583 25. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, et al. Cystatin C and the risk
584 of death and cardiovascular events among elderly persons. *New England Journal of Medicine*.
585 2005;352(20):2049-60.
- 586 26. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a
587 marker of kidney function: a meta-analysis. *American journal of kidney diseases*. 2002;40(2):221-6.
- 588 27. Lu AT, Quach A, Wilson JG, Reiner AP, Aviv A, Raj K, et al. DNA methylation GrimAge strongly
589 predicts lifespan and healthspan. *Aging (Albany NY)*. 2019;11(2):303.
- 590 28. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. Comparison of
591 Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the
592 General Population. *American Journal of Epidemiology*. 2017;186(9):1026-34.
- 593 29. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access
594 resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS*
595 *medicine*. 2015;12(3):e1001779.
- 596 30. UK Biobank. *UK Biobank Haematology Data* [Internet]. Updated 2017. Cited 14 June 2022.
597 Available at: <https://biobank.ndph.ox.ac.uk/showcase/showcase/docs/haematology.pdf>.
- 598 31. UK Biobank. *Companion Document to Accompany Serum Biomarker Data* [Internet]. Updated
599 2019. Cited 14 June 2022. Available
600 at:https://biobank.ndph.ox.ac.uk/showcase/showcase/docs/serum_biochemistry.pdf.
- 601 32. UK Biobank. *Companion Document to Accompany HbA1c Biomarker Data* [Internet]. Updated
602 2018. Cited 14 June 2022. Available at:
603 https://biobank.ndph.ox.ac.uk/ukb/ukb/docs/serum_hb1ac.pdf.
- 604 33. Bodinier B, Filippi S, Nost TH, Chiquet J, Chadeau-Hyam M. Automated calibration for stability
605 selection in penalised regression and graphical models: a multi-OMICs network application exploring
606 the molecular response to tobacco smoking. *arXiv preprint arXiv:210602521*. 2021.
- 607 34. Engebretsen S, Bohlin J. Statistical predictions with glmnet. *Clinical epigenetics*. 2019;11(1):1-
608 3.
- 609 35. Chadeau-Hyam M, Bodinier B, Elliott J, Whitaker MD, Tzoulaki I, Vermeulen R, et al. Risk
610 factors for positive and negative COVID-19 tests: a cautious and in-depth analysis of UK biobank data.
611 *International journal of epidemiology*. 2020;49(5):1454-67.
- 612 36. Therneau T, Lumley T. R survival package. R Core Team. 2013.
- 613 37. Hastie T, Qian J, Tay K. An Introduction to glmnet. CRAN R Repository. 2021.
- 614 38. R-Core-Team. R: A language and environment for statistical computing. Vienna, Austria.: R
615 Foundation for Statistical Computing; 2022.
- 616 39. Joshi PK, Pirastu N, Kentistou KA, Fischer K, Hofer E, Schraut KE, et al. Genome-wide meta-
617 analysis associates HLA-DQA1/DRB1 and LPA and lifestyle factors with human longevity. *Nature*
618 *communications*. 2017;8(1):1-13.
- 619 40. Office for National Statistics. *English Life Tables No. 17* [Internet]. Cited 26 June 2022.
620 Available at:
621 <https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/bulletins/englishlifetablesno17/2015-09-01>.
- 622 41. Kassambara A, Kosinski M, Biecek P, Fabian S. Package 'survminer'. *Drawing Survival Curves*
623 using 'ggplot2'(R package version 03 1). 2017.

- 625 42. Breiman L. Random forests. Machine learning. 2001;45(1):5-32.
626 43. Ishwaran H, Kogalur UB, Kogalur MUB. Package 'randomForestSRC'. breast. 2022;6:1.
627